 |
tetrahydro-N,N-dimethyl-2,2-diphenyl-3-furanmethanamine hydrochloride |
|---|---|
| Trade Name | |
| Orphan Indication | West syndrome |
| USA Market Approval | USA |
| USA Designation Date | 2016-06-20 00:00:00 |
| Sponsor | Anavex Life Sciences Corp.;51 West 52nd Street, 7th Floor;New York, New York, 10019 |
